Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial

详细信息    查看全文

• 作者：Robert Sheldon ; MD ; PhD^a ; ^{sheldon@ucalgary.ca" class="auth_mail" title="E-mail the corresponding author} ; Satish R. Raj ; MD ; MSci^b ; M. Sarah Rose ; PhD^a ; Carlos A. Morillo ; MD^c ; Andrew D. Krahn ; MD^d ; Eduardo Medina ; MD^e ; Mario Talajic ; MD^f ; Teresa Kus ; MD ; PhD^g ; Colette M. Seifer ; MD^h ; Malgorzata Lelonek ; MD ; PhDⁱ ; Thomas Klingenheben ; MD^j ; Ratika Parkash ; MD^k ; Debbie Ritchie ; MN^a ; Maureen McRae ; RN^a ; for the POST 2 InvestigatorsR.S. Sheldon ; S.M. Rose ; D.A. Ritchie ; M. McCrae ; C. Morillo ; V.M. Malcolm ; A.D. Krahn ; B. Spindler ; E. Medina ; M. Talajic ; T. Kus ; A. Langlois ; M. Lelonek ; S. Raj ; C. Seifer ; M. Gardner ; M. Romeo ; P. Poirier ; C. Simpson ; H. Abdollah ; J. Reynolds ; P. Dorian ; D. Birnie ; M. Giuffre ; D. Gilligan ; D. Benditt ; R.S. Sheldon ; S.R. Raj ; M.S. Rose ; A. Krahn ; C. Morillo ; E. Medina
• 关键词：faint ; mineralocorticoid ; recurrence ; reflex
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：5 July 2016
• 年：2016
• 卷：68
• 期：1
• 页码：1-9
• 全文大小：469 K

文摘

There is limited evidence whether being on fludrocortisone prevents vasovagal syncope.

Objectives

The authors sought to determine whether treatment with fludrocortisone reduces the proportion of patients with recurrent vasovagal syncope by at least 40%, representing a pre-specified minimal clinically important relative risk reduction.

Methods

The multicenter POST 2 (Prevention of Syncope Trial 2) was a randomized, placebo-controlled, double-blind trial that assessed the effects of fludrocortisone in vasovagal syncope over a 1-year treatment period. All patients had >2 syncopal spells and a Calgary Syncope Symptom Score >−3. Patients received either fludrocortisone or matching placebo at highest tolerated doses from 0.05 mg to 0.2 mg daily. The main outcome measure was the first recurrence of syncope.

Results

The authors randomized 210 patients (71% female, median age 30 years) with a median 15 syncopal spells over a median of 9 years equally to fludrocortisone or placebo. Of these, 96 patients had ≥1 syncope recurrences, and only 14 patients were lost to follow-up before syncope recurrence. There was a marginally nonsignificant reduction in syncope in the fludrocortisone group (hazard ratio [HR]: 0.69: 95% confidence interval [CI]: 0.46 to 1.03; p = 0.069). In a multivariable model, fludrocortisone significantly reduced the likelihood of syncope (HR: 0.63; 95% CI: 0.42 to 0.94; p = 0.024). When the analysis was restricted to outcomes after 2 weeks of dose stabilization, there was a significant benefit due to fludrocortisone (HR: 0.51; 95% CI: 0.28 to 0.89; p = 0.019).

Conclusions

The study did not meet its primary objective of demonstrating that fludrocortisone reduced the likelihood of vasovagal syncope by the specified risk reduction of 40%. The study demonstrated a significant effect after dose stabilization, and there were significant findings in post hoc multivariable and on-treatment analyses. (A randomised clinical trial of fludrocortisone for the prevention of vasovagal syncope; ISRCTN51802652; Prevention of Syncope Trial 2 [POST 2]; NCT00118482)